Search Weight Loss Topics:

Page 11«..10111213..2030..»

Home » Long Term Weight Loss » Page 11

THURSDAY, Dec. 28, 2023 (HealthDay News) -- New research offers yet more evidence that veggies, whole grains and low-fat dairy products are good for you in the long run.

"Our study goes beyond the simple question of, 'To carb or not to carb?'" said lead study author Binkai Liu, a research assistant in the nutrition department at Harvard T.H. Chan School of Public Health in Boston.

"It dissects the low-carbohydrate diet and provides a nuanced look at how the composition of these diets can affect health over years, not just weeks or months," Liu explained in a Harvard news release.

The key takeaway: Not all low-carb diets are the same when it comes to managing weight over the long haul.

In the study, researchers analyzed data from more than 123,000 healthy adults who were part of major research studies between 1986 and 2018.

Participants reported on their diets and weights every four years, and they were scored based on adherence to five types of low-carb diet. They included ones based on animal proteins, plant-based proteins and ones that emphasized animal proteins, unhealthy fats and processed grains.

Low-carb regimens high in proteins, fats and carbs from healthy, plant-based sources were linked to slower long-term weight gain.

Participants who stuck with total low-carb or animal-based eating regimens gained more weight, on average, than those who followed a healthy low-carb eating plan over time.

These links were strongest for participants who were overweight or obese, younger than 55 and/or less physical active, the study found.

The findings were published Dec. 27 in the journal JAMA Network Open.

"Our findings could shake up the way we think about popular low-carbohydrate diets and suggest that public health initiatives should continue to promote dietary patterns that emphasize healthful foods like whole grains, fruits, vegetables and low-fat dairy products," said senior study author Dr. Qi Sun, an associate professor of nutrition at Harvard.

More information

The Mayo Clinic has more about low-carb diets.

SOURCE: Harvard University T.H. Chan School of Public Health, news release, Dec. 27, 2023

See the rest here:
Going Low-Carb? Avoid Meat to Keep the Weight Off Long-Term - HealthDay

The world of diets is a confusing one, filled with countless theories and strategies, each claiming to be the ultimate solution for weight loss and health. Among the most popular are low-carb and no-carb diets. However, these diets may lead us to miss out on many delicious and healthy foods. It is crucial to understand the difference between healthy carbohydrates, often found in whole foods, and less healthy ones, typically found in processed foods. This article aims to provide valuable insights for those considering a low-carb or no-carb diet.

Refined carbohydrates, also known as simple carbs, come in two forms: refined grains and sugars. The refining process eliminates the bran and germ, leaving only the endosperm, which significantly reduces the nutritional value. Consumption of too many refined carbs is associated with an increased risk of obesity, heart disease, metabolic syndrome, and type 2 diabetes. Common examples of refined carbohydrates include white bread, white rice, and white flour. Hence, it is advisable to consume these foods in moderation and opt for complex carbohydrates, which are digested more slowly and are richer in nutrients.

A study conducted by Harvard found that the quality of foods, not just the quantity of carbohydrates, fats, and proteins, makes a difference in maintaining weight. The research, which followed the eating patterns of 120,000 people over 30 to 40 years, found that diets composed of plant-based proteins and fats, and healthy carbohydrates were significantly associated with slower long-term weight gain than unhealthy low-carb diets. This study confirms that the quality of diet matters, not just the number of carbs.

Complex carbs digest or absorb more slowly than simple carbs, which can aid in weight control and maintaining stable blood sugar levels. They are also more filling, which can help prevent overeating. The timing of consuming carbs can also play a role, with simple carbs being suggested for energy before or after intense workouts, and before bed for faster digestion and energy.

A study of nearly 125,000 healthy adults showed that replacing refined carbs with whole-grain foods and reducing animal-based fats and proteins lessened the amount of weight people gained over four years. The research emphasized the importance of high-quality carbohydrates such as whole grains, healthy fats, and plant-based proteins. Moreover, it showed that diets heavy on healthy carbohydrates and plant-based proteins and fats are associated with significantly slower long-term weight gain. However, even healthy choices can become unhealthy depending on how they are served.

Reducing refined carbs can lead to weight loss and decrease the risk of heart disease. Consuming fibrous vegetables and natural fats can also aid in weight loss and disease prevention. However, it is crucial to note the potential risks of low-carb diets and the dangers of increasing carbohydrate intake to very high levels. The connection between carbs and weight loss is complex and depends on the quality and quantity of the carbs consumed.

While low-carb and no-carb diets can seem attractive for quick weight loss, its essential to consider the long-term effects and benefits of whole, unprocessed foods. By focusing on the quality of carbohydrates and including a balance of healthy fats and proteins in our diet, we can enjoy delicious food, maintain a healthy weight, and reduce the risk of chronic diseases.

See the original post:
The Role of Carbohydrates in Weight Loss and Disease Reduction - Medriva

Low-carbohydrate diets comprised mostly of plant-based proteins and fats with healthy carbohydrates such as whole grains were associated with slower long-term weight gain than low-carbohydrate diets comprised mostly of animal proteins and fats with unhealthy carbohydrates like refined starches, according to a new study led by Harvard T.H. Chan School of Public Health.

The study will be published on December 27, 2023, inJAMA Network Open.

Our study goes beyond the simple question of, To carb or not to carb? said lead author Binkai Liu, research assistant in the Department of Nutrition. It dissects the low-carbohydrate diet and provides a nuanced look at how the composition of these diets can affect health over years, not just weeks or months.

While many studies have shown the benefits of cutting carbohydrates for short-term weight loss, little research has been conducted on low-carbohydrate diets effect on long-term weight maintenance and the role of food group quality.

Using data from the Nurses Health Study, Nurses Health Study II, and Health Professionals Follow-up Study, the researchers analyzed the diets and weights of 123,332 healthy adults from as early as 1986 to as recently as 2018. Each participant provided self-reports of their diets and weights every four years. The researchers scored participants diets based on how well they adhered to five categories of low-carbohydrate diet: total low-carbohydrate diet (TLCD), emphasizing overall lower carbohydrate intake; animal-based low-carbohydrate diet (ALCD), emphasizing animal-based proteins and fats; vegetable-based low-carbohydrate diet (VLCD), emphasizing plant-based proteins and fats; healthy low-carbohydrate diet (HLCD), emphasizing plant-based proteins, healthy fats, and fewer refined carbohydrates; and unhealthy low-carbohydrate diet (ULCD), emphasizing animal-based proteins, unhealthy fats, and carbohydrates coming from unhealthy sources such as processed breads and cereals.

The study found that diets comprised of plant-based proteins and fats and healthy carbohydrates were significantly associated with slower long-term weight gain. Participants who increased their adherence to TLCD, ALCD, and ULCD on average gained more weight compared to those who increased their adherence to HLCD over time. These associations were most pronounced among participants who were younger (<55 years old), overweight or obese, and/or less physically active. The results for the vegetable-based low carbohydrate diet were more ambiguous: Data from the Nurses Health Study II showed an association between higher VLCD scores and less weight gain over time, while data around VLCD scores from the Nurses Health Study and Health Professionals Follow-up Study were more mixed.

The key takeaway here is that not all low-carbohydrate diets are created equal when it comes to managing weight in the long-term, said senior author Qi Sun, associate professor in the Department of Nutrition. Our findings could shake up the way we think about popular low-carbohydrate diets and suggest that public health initiatives should continue to promote dietary patterns that emphasize healthful foods like whole grains, fruits, vegetables, and low-fat dairy products.

Other Harvard Chan authors included Molin Wang, associate professor in the Departments of Epidemiology and Biostatistics, and Yang Hu, research scientist; Sharan Rai, postdoctoral research fellow; and Frank Hu, professor, in the Department of Nutrition.

The study was funded by research grants from the National Institutes of Health: UM1 CA186107, U01 CA176726, U01 CA167552, P01 CA87969, R01 HL034594, R01 HL035464, R01 HL60712, R01 DK120870, R01 DK126698, R01 DK119268, U2C DK129670, DK119268, R01 ES022981, and R21 AG070375.

Low-Carbohydrate Diet Macronutrient Quality and Weight Change, Binkai Liu, Yang Hu, Sharan K. Rai, Molin Wang, Frank B. Hu, Qi Sun,JAMA Network Open, December 27, 2023, doi: 10.1001/jamanetworkopen.2023.49552

The material in this press release comes from the originating research organization. Content may be edited for style and length. Want more? Sign up for our daily email.

See the article here:
Low-carbohydrate diets emphasizing healthy, plant-based sources associated with slower long-term weight gain - ScienceBlog.com

The current class of anti-obesity drugs is proving remarkably effective at removing excess pounds. However, a phase 3 randomized clinical trial led by researchers at Weill Cornell Medicine and NewYork-Presbyterian found that people who stopped taking the medication regained much of that weight within a year. At the same time, the study shows that remaining on the drug not only promotes additional weight loss but preserves improvements in metabolic and cardiovascular health.

The results from the SURMOUNT-4 study, which appeared Dec. 11 in JAMA and was sponsored by Eli Lilly and Company, demonstrated that the drug can substantially help people struggling with health issues related to their weight, but it is not a quick-fix to weight loss.

Obesity is a leading driver of many diseases that we spend our time treating in medicine; illnesses like hypertension, heart disease, diabetes and fatty liver disease are either caused by or worsened by obesity, said lead study author Dr. Louis Aronne, the Sanford I. Weill Professor of Metabolic Research and director of the Comprehensive Weight Control Center, which is part of the Division of Endocrinology, Diabetes, and Metabolism at Weill Cornell Medicine. The fact that we now have drugs that are proving to be effective is exciting and rewarding.

Tirzepatide is part of a new class of drugs called called GLP-1 receptor agonists that were developed to treat type 2 diabetes. Besides controlling blood sugar, the drugs also resulted in weight loss, so pharma companies created specific formulations to help patients shed pounds.

In 2022, a phase 3 randomized, controlled clinical trial demonstrated that tirzepatide led to a 20 percent reduction in body weight over 72 weeks. The findings prompted the U.S. Food and Drug Administration to approve the drug last month, with the trade name Zepbound, for weight loss in individuals with a body mass index (BMI) of 30 or higheror for those with a BMI of 27 or greater who also had health conditions such as high cholesterol or hypertension.

Although the initial effects were dramatic, the researchers were uncertain whether the weight loss would persist beyond the period of active treatment. To find out, they launched the SURMOUNT-4 trial, which was conducted at 70 sites in Argentina, Brazil, Taiwan and the United States between March 2021 and May 2023. The participants took a maximum tolerated dose of tirzepatide for 36 weeks, which yielded the expected weight reduction of 20.9 percent with improvements in blood pressure, blood sugar metrics and lipid levels.

Then 670 eligible participants were randomly assigned to either continue with the tirzepatide for an additional year (52 weeks) or to switch to a placebo. Those who continued on tirzepatide lost an additional 5.5 percent versus the placebo group which regained 14 percent of their weight.

Though the placebo group was still almost 10 percent lighter than their initial weight, the improvements in cardiometabolic risk factors had been reversed. Relative to placebo, tirzepatide was associated with significant improvements in BMI, lipid levels, diabetes indicators and blood pressure.

Dr. Louis Aronne

Those who went on the placebo regained about half the weight they had lost, said Dr. Aronne, who is also an internist specializing in diabetes and obesity at NewYork-Presbyterian/Weill Cornell Medical Center. Whereas those who continued on the drug lost another 5 percent, so their overall weight loss was about 25 percent.

The findings indicate that people may need to remain on tirzepatide to keep off the pounds. If you stop the medication, you regain the weight. Theres no question that will happen, said Dr. Aronne. But that shouldnt be surprising. Obesity is a chronic condition, like diabetes or high blood pressure. So, it must be treated chronically.

The researchers noted that they didnt evaluate the effects of intensive behavioral therapy on the maintenance of body weight reduction, which could make a difference in preventing weight regain after coming off the drug.

Tirzepatide works by mimicking the GLP-1 and GIP hormones that are naturally secreted by the intestine after a meal, which prompts insulin secretion. It also reduces appetite by slowing down the time it takes the stomach to empty and interacting with areas in the brain harboring GLP-1 receptors to signal satiety.

Instead of counting calories, the medicine helps a person eat less because it signals to the brain that youre full, said Dr. Aronne. The dual mechanism of action helps overcome the plateau phenomenon that is seen at some point and produces additive weight loss.

Since the drug mimics hormones that are produced in the gastrointestinal system, side effects tended to be nausea, vomiting, diarrhea or constipation and resolved with time. The study had few people dropout because of side effects.

People feel much better when they lose this kind of weight, so they are extremely enthusiastic about these treatments. But they also should realize this may require them to stay on the drug long term, said Dr. Aronne. Further studies will need to assess the long-term risks and benefits associated with these drugs, especially considering the potential for their lifelong use.

Many Weill Cornell Medicine physicians and scientists maintain relationships and collaborate with external organizations to foster scientific innovation and provide expert guidance. The institution makes these disclosures public to ensure transparency. Dr. Louis J. Aronne serves as a paid advisory board member for Eli Lilly and Company. For further information, see the profile for Dr. Louis Aronne.

Follow this link:
Tirzepatide Enhances Weight Loss with Sustained Treatment but Discontinuation Leads to Weight Regain - Weill Cornell Medicine Newsroom

The Big Picture: Dr. Adriana Davis, Family Medicine, "The idea here is to know that drugs like Ozempic and Mounjaro are being used for chronic disease conditions--and you may have to take these medicines indefinitely." Doctor's Expert Insights About Weight Loss and Drugs like Tirzepatide and Ozempic in Missouri

Know this: "So, this study shows significant weight loss with tirzepatide, but highlights a challenge: stopping the drug often leads to weight regain. This isn't about willpower--it's about understanding that obesity is a chronic condition that may require ongoing medication. Like many other chronic diseases, obesity needs to be managed. It will require ongoing pharmacotherapy and lifestyle changes. This study serves as a reminder that weight management is a long-term commitment and requires sustained medical and lifestyle interventions. Also, as I've been recommending here, make sure that you know your A1C and blood cholesterol levels. Knowing these metrics will be important in guiding how you and your healthcare team treat and manage obesity." Dr. Puja Uppal, Family Medicine.

Beyond the news: These findings are creating a paradigm shift in how obesity is treated and managed--with an emphasis on long-term pharmacological intervention and lifestyle changes.

Key Findings:

"After 36 weeks of open-label maximum tolerated dose of tirzepatide (10 or 15 mg), adults (n=670) with obesity or overweight (without diabetes) experienced a mean weight reduction of 20.9%. From randomization (at week 36), those switched to placebo experienced a 14% weight regain and those continuing tirzepatide experienced an additional 5.5% weight reduction during the 52-week double-blind period." (Study Source)

Key Drivers in St. Louis County:

The study highlighted tirzepatide's efficacy in maintaining and augmenting initial weight loss in individuals who were overweight.

Participants that continued tirzepatide after an initial 36-week period experienced an additional 5.5% weight reduction of their body weight. But, those who were switched to a placebo regained an average of 14.4% of their body weight.

The study also noted improvements in cardiometabolic risk factors with tirzepatide use--this is significant for overall health outcomes.

What they're saying: "The consistency of these data across therapeutic classes spanning more than 2 decades suggests that obesity is a chronic metabolic condition similar to type 2 diabetes and hypertension requiring long-term therapy in most patients.

A notable finding in the SURMOUNT-4 trial is that after switching to placebo for 1 year, participants ended the study with substantial body weight reduction (9.9%). However, much of their initial improvement in cardiometabolic risk factors had been reversed. Further studies are needed to understand the potential long-term benefits and risks (ie, legacy effects) of such short-term therapy." (Study Source)

Health Standard Newswire: To keep the advantages gained from weight loss medications, it may be necessary to continue using them for the long term.

All of these variables above play an important role in the outcomes of your overall health.

The Health Standard Newswire.

Continued here:
St. Louis Health Alert: Should I Keep Taking Tirzepatide for Weight Loss Success? Doctor Explains - Branson Tri-Lakes news

A New Hope in Weight Loss Treatment

A recent study in the Journal of the American Medical Association has shed light on the potential of a novel therapeutic approach, tirzepatide, in managing obesity in adults. The drug, a combination of GLP-1 and glucose-dependent insulinotropic polypeptide agonism, produced synergistic effects on food intake, appetite, and metabolic function, thus facilitating significant weight loss and improved metabolic health in obese individuals.

The trial, known as SURMOUNT-4, was a randomized withdrawal study conducted across the United States, Argentina, Taiwan, and Brazil. Over the course of the study, 670 participants were randomized to continue treatment with the maximum tolerated dose of tirzepatide or receive a placebo. The results were compelling. The average percent change in weight from weeks 36 to 88 was 5.5% with tirzepatide and 14% with placebo. Furthermore, by week 88, a significantly higher percentage of tirzepatide recipients maintained at least 80% of the weight loss achieved during the lead-in period.

Continued treatment with tirzepatide was associated with significant improvements in BMI, glycated hemoglobin, fasting glucose, blood pressure, insulin, and lipid levels by week 88. These improvements in cardiometabolic risk factors underscore the potential of tirzepatide in providing holistic patient care. Beyond weight loss, the drug could have far-reaching implications for managing chronic conditions such as diabetes, hypertension, and high cholesterol levels.

The SURMOUNT-4 trials findings highlight the importance of long-term pharmacotherapy in weight management. Participants who continued to take tirzepatide lost an additional 5.5 percent of their weight, while those who switched to a placebo regained about half the weight lost. More than 90% of patients who continued taking the medication kept the weight off, while only 16.6% of those who received a placebo were able to maintain their weight loss. This emphasizes the need to treat obesity as a chronic disease, warranting long-term management strategies similar to other chronic conditions like high blood pressure.

While tirzepatide shows promise, its crucial to consider the potential side effects and long-term risks. The cost of the medication, the possible side effects, and the need for sustained medication use are all factors to weigh against the health risks associated with untreated obesity. As tirzepatide and similar medications become more prevalent, medical professionals must familiarize themselves with these drugs benefits and potential drawbacks to provide balanced, comprehensive patient care.

The SURMOUNT-4 trials findings represent a significant step forward in the management of obesity. Tirzepatides demonstrated efficacy in maintaining long-term weight loss and improving cardiometabolic health highlights its potential as a game-changing therapeutic approach. As the medical community continues to explore the long-term risks and benefits of medications like tirzepatide, patients and healthcare providers can look forward to more effective strategies in the battle against obesity.

Read the original:
New Hope in Weight Loss Treatment: Tirzepatide Study Reveals Promising Results - Medriva

Weight-inclusive health care means a focus on better health with no weight loss required.

This includes practices such as eating for overall well-being rather than for the number of calories. It may also include prioritizing activities to reduce stress, avoiding smoking, drinking less alcohol and striving to be physically active in enjoyable ways.

A weight-inclusive approach to health seeks to undo the harms caused by weight stigma.

People with larger bodies often experience weight stigma as discrimination, prejudice, negative stereotypes and judgments from others including their own doctors and other health care providers. More than 40% of U.S. adults across a range of body sizes report experiencing weight stigma in their day-to-day lives.

Avoiding this stigma is likely a major driver behind the great lengths people in the U.S. go to in order to lose weight. Market data shows that Americans spent some US$72.6 billion on weight loss products and programs in 2021. In addition, weight loss efforts start early, with nearly half of all high school students in the U.S. reporting that they have tried to lose weight.

I am a nutrition epidemiologist and registered dietitian studying the consequences of weight stigma and working to develop weight-inclusive nutrition interventions.

Initially my private practice and research approach were weight-centered. A weight-centered approach focuses on weight loss to achieve health and is widely accepted in health care settings across the world. After over a decade of work in public health nutrition, I have witnessed how, in my view, the weight-centered approach harms individuals and communities. So I have shifted to using a weight-inclusive approach in practice and research.

There is an extensive body of research and public health messaging indicating that higher body weight has links with many long-term health concerns, such as high blood pressure and Type 2 diabetes.

As a result, there is a pervasive misconception that a weight-inclusive approach disregards the patients health concerns. However, proponents of weight-inclusive care argue that a weight-inclusive approach minimizes health problems by destigmatizing weight status and promoting health equity. They also acknowledge that there are links between both higher and lower body weight and various health concerns.

The dogma that lower weight is synonymous with better health is being questioned by public health researchers and health care providers. Scientists and clinicians are calling for a paradigm shift away from a weight-centered focus on weight status and body mass index, or BMI, as indicators of health.

Advocacy groups like the Association for Size Diversity and Health have long been promoting the Health at Every Size approach. This weight-inclusive approach affirms a socially just definition of health and advocates for equitable health care regardless of weight status. More recently, the American Medical Association released a statement outlining the harms and shortcomings of using BMI as a clinical measurement.

Substantial research shows that behaviors such as stopping smoking and drinking less alcohol can prevent disease and support overall long-term health, regardless of body weight. For example, a systematic review of one clinical trial and 152 observational peer-reviewed studies reported that a diet high in nutrient-rich foods with low or moderate alcohol consumption is associated with reduced risk of death for everyone.

Another example: One of my own clients with high cholesterol said that focusing on weight loss over their lifetime had left them stuck in a cycle of weight loss and weight regain, disordered eating, inconsistent and extreme exercise habits and body image concerns. After adopting weight-inclusive practices such as eating more fiber-rich foods and being more physically active, instead of focusing on losing weight, their cholesterol levels returned to normal.

Both the weight-inclusive approach and the weight-centered approach can include diet changes, increasing physical activity and reducing stress as key components to manage and prevent diseases. However, the weight-inclusive approach works to end weight stigma and acknowledges that factors such as socioeconomic status, culture and access to food and health care collectively called the social determinants of health have huge impacts on a persons body weight, shape and size. Even if a person could adhere to strict dieting and exercise routines, there will always be structural, political and other factors affecting health and weight that the individual cant control.

Whats more, evidence indicates that people who lose weight generally dont have better long-term health and fail to keep those pounds off.

There are several things that people can look for in a weight-inclusive health care practice.

Look for health care providers who:

For additional resources on weight-inclusive care, check out the Health at Every Size Health Sheets. Consider examining your own weight bias by taking an online test focused on implicit associations around weight.

Here is the original post:
What does weight-inclusive health care mean? A dietitian explains what some providers are doing to end weight stigma - The Conversation

Celery is an underrated and versatile vegetable. You can dip it in hummus, spread peanut butter on it, add it to salads and smoothies, or enjoy it on its own for a satisfying, crunchy snack. Regardless of how you choose to eat celery, it makes for a nutrient-dense snack option that deserves a place in any weight loss diet plan. That's why we spoke with Destini Moody, RDN, CSSD, LD, a registered dietitian and sports dietitian with Garage Gym Reviews, who shares her expert wisdom on how eating celery can help you lose weight and keep it off.

The benefits of eating celery go far beyond weight loss. One study found that the antioxidants in celery can boost heart health by reducing high blood pressure and helping control blood sugar. Other research points out that celery has anti-inflammatory properties that can help minimize the risk of cancer, heart disease, and diabetes.

If you're curious about how celery can aid your weight loss journey, read on to learn more. And, when you're done, don't miss How Many Calories Are In a Cucumber?

Celery is nutrient-dense, meaning it packs plenty of nutritional value without a ton of calories. According to the USDA, one medium celery stalk contains approximately 23 calories. Celery also has a high water content (between 90 to 99% water) and is an excellent source of soluble and insoluble fiber, which can help fill you up and prevent overeating.

"Including celery in a weight loss diet as an ingredient in healthy recipes or just as a snack is a great way to support weight loss," states Moody.

RELATED: 9 Lazy Ways to Lose Weight All Month Long

Now that we've confirmed celery can help you shed unwanted pounds, here are five reasons why it's an excellent addition to a healthy diet, according to Moody.

Celery is a weight-loss-friendly vegetable primarily due to its incredibly low-calorie count. With almost negligible calories, it allows you to indulge in a satisfying crunch without sabotaging your weight loss efforts. This makes celery an excellent choice for those looking to shed pounds while enjoying a refreshing, guilt-free snack.

Moody tells us, "One cup of chopped celery contains a measly 16 calories, so you're very unlikely to gain weight after indulging in celery in large quantities." 6254a4d1642c605c54bf1cab17d50f1e

RELATED: 10 Best Frozen Foods To Buy at Whole Foods for Weight Loss

As a crunchy and hydrating snack, celery's natural crispiness makes it a satisfying alternative to less healthy snacks like chips or sugary treats. Including celery in your snack routine is a health-conscious choice that can support your weight loss journey.

RELATED: 10 Essential Grocery Store Buys for Weight Loss

"Due to how low in calories the vegetable is, it's a great substitute for snacks that may have been higher in calories like granola bars or potato chips," Moody explains. "Also, instead of using tortilla or pita chips as a vessel for your favorite snack dips and sauces, swapping celery is a great way to cut down on calories from snacking."

Celery's high water and fiber content bulks up meals without adding extra calories. This means you can enjoy larger portions and feel more satiated, reducing the temptation to overeat. Try including celery in salads, stir-fries, or alongside your main dishes to boost the volume of your meals and increase satiety.

"Add celery to meals like soups, stews, and salads to add more volume to your meals without adding calories," says Moody. "This will make for low-calorie yet satisfying recipes to add to your weight loss diet."

RELATED: 10 Common Nighttime Habits That Can Make You Gain Weight

Fiber helps you feel fuller longer and improves digestiontwo critical components of long-term weight loss.

"Anyone who's snacked on celery knows it's made up of tough little fibers, and these fibers don't digest quickly," Moody explains. "This is good news for those trying to lose weight as this slows gastric emptying, meaning your stomach stays fuller for longer, which stops you from overeating throughout the day."

If your health goal is to lose weight, staying hydrated is critical for success. And with its high water content, celery is a fantastic snack option for those looking to shed some extra pounds.

"Studies have shown that the body [can mistake] thirst for hunger so staying hydrated is paramount when you're trying to manage your weight," says Moody. "High-water veggies like celery can help hydrate you and satisfy your hunger at the same time."

Sign up for our newsletter!

Original post:
Can Eating Celery Help You Lose Weight? - Eat This, Not That

Sharon Osbourne is getting candid about her weight loss from Ozempic and how husband Ozzy Osbourne is worried that she's putting her health at risk.

During an appearance on Good Morning Britain on Friday, Sharon, 71, admitted that the "Crazy Train" rocker, 74, isn't thrilled about her slimmer physique and how she's achieved it. "He doesn't like it," she said, explaining that he feels she's lost too much weight.

"And he's scared that something us going to happen to me," Sharon continued, referring to her use of the Type 2 diabetes drug. "He says, 'You've got skinny then something else is going to happen.' He's always thinking about the downside that it's too good to be true."

Sharon agreed that she could stand to put on "a few pounds," but said her body is at a point where it's "not listening, it's staying where it is."

The former The Talk host said she first decided to take Ozempic because she was "fed up" with struggling with her weight. "I just thought, 'I've tried everything so I might as well try this,' /" she explained.

Despite her husband's worries about potential long-term side effects, she has found that the medication works well for her. "I mean, look, it does what it says on the packet. It absolutely does," she noted.

She did, however, voice her own concerns about Ozempic and similar drugs being used by younger people. "I don't think it's for teenagers at all. I'm scared for like 16- to 20-year-olds because it's easy to say, 'This is it. I can eat what I want. I keep taking this injection and I'm like this,' " she explained.

"I just think it needs to be in the hands of older people, who totally understand there could be side effects to this," she added.

Katja Ogrin/Getty

Never miss a story sign up for PEOPLE's free daily newsletter to stay up-to-date on the best of what PEOPLE has to offer, from juicy celebrity news to compelling human interest stories.

During her GMB appearance, Sharon also touched on Ozzy's significant health challenges, saying the Black Sabbath vocalist has been through "five years of nightmares and operations" on his neck and spine to repair structural damage he sustained after a 2019 fall.

"I do not know how he has withstood it," she said.

Ozzy himself opened up about his health in a recent interview with Rolling Stone UK. Its really knocked me about, he said of having to undergo four surgeries. The second surgery went drastically wrong and virtually left me crippled. I thought Id be up and running after the second and third, but with the last one they put a fucking rod in my spine. They found a tumor in one of the vertebrae, so they had to dig all that out too. Its pretty rough, man."

Sharon told the outlet that it's been difficult for her to see her husband endure so much. "Ive just felt so helpless and so bad for Ozzy, to see him going through the pain," she said.

Read the original here:
Sharon Osbourne Says Ozzy Osbourne 'Doesn't Like' Her Weight Loss - PEOPLE

Medtronic Plc logo is seen displayed in this illustration taken, April 10, 2023. REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing Rights

Nov 21 (Reuters) - Medtronic (MDT.N) raised its annual earnings forecast on Tuesday as strong sales in its surgical and diabetes units allayed concerns about the impact of new diabetes and weight-loss drugs on long-term growth, sending its shares up nearly 4% in morning trade.

Makers of medical products used in bariatric surgery and glucose-monitoring devices have been trying to ease investor concerns over a potential hit to demand from the rising popularity of new GLP-1 drugs like Novo Nordisk's (NOVOb.CO) Ozempic and Eli Lilly's (LLY.N) Mounjaro.

Medtronic's CEO Geoffrey Martha said GLP-1 drugs would have a modest but temporary impact on the bariatric surgery market.

Dublin-based Medtronic joins peers Johnson and Johnson (JNJ.N) and Abbott Laboratories (ABT.N) in playing down the impact of GLP-1 drugs, which suppress hunger in patients.

"Bariatric surgery will continue to remain the gold standard for addressing obesity," Martha said, adding that many patients who try these drugs will not stay on them for more than a year due to concerns related to costs and side effects.

Over the long term, health care costs may be delayed with the use of GLP-1s but not eliminated, limiting the impact on medical-device companies, said John Boylan, analyst at Edward Jones.

When asked about a possible spin-off or sale of its respiratory and patient-monitoring units, Martha confirmed to Reuters that Medtronic is continuing to work on the separation, which is expected by the first half of the next fiscal year.

Sales in Medtronic's diabetes unit stood at $610 million, beating estimates of $588.4 million. Martha expects diabetes devices to drive the company's sales growth in the second half of the fiscal year.

It now estimates profit per share between $5.13 and $5.19 for the fiscal year ending in April 2024, above the previous $5.08 to $5.16 per share range.

Medtronic beat adjusted profit by 7 cents for the quarter ended Oct. 27, according to LSEG data.

Reporting by Khushi Mandowara and Christy Santhosh in Bengaluru; Editing by Pooja Desai

Our Standards: The Thomson Reuters Trust Principles.

See more here:
Medtronic shrugs off concerns over newer weight-loss drugs, raises ... - Reuters

Page 11«..10111213..2030..»

Home » Long Term Weight Loss » Page 11